Key points from article :
Announcing “substantial doubt” about its ability to continue as money runs dry and debts mount.
Recorded $12,000 in revenue but $1.6 million in operating expenses for the second quarter.
AgeX had borrowed $10.2 million from Juvenescence with $3 million line of credit is available until Feb. 14, 2023.
AgeX currently has three preclinical candidates targeting cardiac ischemia, scarless wound repair, and age-related metabolic disorders such as Type II diabetes.
AgeX was launched in 2017 as a subsidiary of BioTime (now Lineage Cell Therapeutics).
